Guggenheim Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $43

Benzinga Newsdesk www.benzinga.com Negative 48.5%

Neg 48.5% Neu 0% Pos 0%

Guggenheim analyst Debjit Chattopadhyay maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and lowers the price target from $52 to $43.